Case 1: Frontline Medical Group is a regional managed care organization that would like to report HEDIS data to improve the quality of care provided to in-plan members suffering from major depressive disorder.

Case Study

Faculty

Jeffrey D. Dunn, PharmD, MBA
Formulary and Contract Manager
SelectHealth, Inc.
Salt Lake City, Utah

Suzy Harrington, DNP, MS, RN, MCHES
Director of Customer Resources
National Committee for Quality Assurance (NCQA)
Washington, DC

Intended Learners

This activity is designed for managed markets physicians and pharmacists, pharmacy directors, medical directors, formulary decision makers, and other managed care professionals.

Learning Objectives

After completing this activity, participants should be able to:

Develop strategies that aim to lower overall medical costs and improve outcomes in covered patients with major depressive disorder (MDD) and treatment-resistant depression (TRD)
Describe the utility of depression-related HEDIS measures on plan performance and patient adherence

Activity Overview

This on-demand case vignette activity consists of a patient case study, with polling questions integrated throughout the case.

To be eligible for documentation of credit, participants must review the case study, answer all polling questions, complete the 5-question online post-test with a score of 80% or better, and complete the evaluation form. After successful completion of the post-test and evaluation form online at www.naccme.com, participants may immediately print their documentation of credit.

Release date: September 30, 2011
Expiration date: September 30, 2012

Estimated time to complete: 30 minutes

There is no fee associated with this activity.

This educational activity is a knowledge-based activity.

For questions regarding this activity, please call 609-371-1137.

Hardware/Software Requirements

All educational activities are accessible via a PC (Windows 2000/XP/Vista/7) or Mac (Mac OS 10.x or later) computer with current versions of the following browsers: Internet Explorer, Mozilla Firefox, Google Chrome, or Safari. Windows Media Player or compatible alternative, sound card, and speakers are required for streamed audio. The latest version of the Adobe Flash Player is suggested (please download here) for video programs. A PDF reader is required for print publications. Please direct technical questions to webmaster@naccme.com.

Accreditation

This activity has been planned and implemented by North American Center for Continuing Medical Education, LLC and the National Committee for Quality Assurance for the advancement of patient care. North American Center for Continuing Medical Education, LLC (NACCME) is accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

CME

NACCME designates this enduring material for a maximum of .5 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

CPE

This activity is approved for .5 contact hour (0.05 CEU) of continuing pharmacy education (UAN 276-999-11-050-H01-P).

Any participant wanting to file a grievance with respect to any aspect of a continuing pharmacy education activity accredited by NACCME may contact the Assistant Director, Accreditation Services, NACCME, in writing at 300 Rike Drive, Suite A, Millstone Township, NJ 08535. The Assistant Director, Accreditation Services will review the grievance and respond within 30 days of receiving the written statement. If the participant is unsatisfied with the response, an appeal to the Senior Director, Accreditation Services, NACCME, may be made for a second level of review.

Independent Clinical Reviewer: Bradley N. Gaynes, MD, MPH, Professor of Psychiatry, University of North Carolina School of Medicine, Chapel Hill, North Carolina

Planning Committee

The planning committee comprises of William J. Cardarelli, PharmD, K. Ryan Connolly, MD, Jeffrey D. Dunn, PharmD, MBA, Charles B. Nemeroff, MD, PhD, Suzy Harrington, DNP, MS, RN, MCHES, and Bradley N. Gaynes, MD, MPH; Stephen Chavez, Laura D'Onofrio, Mary Johnson, Mike Kearney, Nick Lombardi, Randy Robbin, John Savage, and Jessica Steuerman, NACCME.

Financial Disclosure and Conflicts of Interest

According to the disclosure policy of NACCME, faculty, editors, managers, and other individuals who are in a position to control content are required to disclose any relevant financial relationships with relevant commercial companies related to this activity. All relevant conflicts of interest that are identified are reviewed for potential conflicts of interest. If a conflict is identified, it is the responsibility of NACCME to initiate a mechanism to resolve the conflict(s). The existence of these interests or relationships is not viewed as implying bias or decreasing the value of the presentation.

All educational materials are reviewed for fair balance, scientific objectivity of studies reported, and levels of evidence.

The faculty has reported the following:

Dr. Dunn: Consultant—Forest Pharmaceuticals, Inc.
Dr. Gaynes: Grant/Research support—Agency for Healthcare Research and Quality, National Institute of Mental Health
Dr. Harrington: Promotional speakers bureau—Astellas, Boehringer-Ingelheim
Dr. Nemeroff: Grant/Research support— Agency for Healthcare Research and Quality, National Institutes of Health; Consultant—Xhale, Inc., Takeda Pharmaceutical Company Limited; Stock shareholder—CeNeRx BioPharma, NovaDel Pharma, Inc., PharmaNeuroBoost, Revaax Pharmaceuticals, LLC, Xhale, Inc.; Scientific advisory boards—American Foundation for Suicide Prevention, Anxiety Disorders Association of America, CeNeRx BioPharma, National Alliance for Research on Schizophrenia and Depression, NovaDel Pharma, Inc., PharmaNeuroBoost; Board of Directors—American Foundation for Suicide Prevention, NovaDel Pharma, Inc.; Other Financial Interests—CeNeRx BioPharma, PharmaNeuroBoost
Dr. Cardarelli and Dr. Connolly have disclosed no relevant financial relationships with any commercial interests.

Mr. Chavez, Ms. D'Onofrio, Ms. Johnson, Mr. Kearney, Mr. Robbin, Mr. Savage, and Ms. Steuerman have disclosed no relevant financial relationships with any commercial interests.

Mr. Lombardi: Stock shareholder—Inspire Pharmaceuticals, Inc., ViroPharma, Inc., Vertex Pharmaceuticals

NACCME requires faculty to inform participants whenever off-label/unapproved uses of drugs and/or devices are discussed in their presentations.

The faculty has disclosed that no off-label/unapproved drugs and/or devices will be discussed.

NACCME protects the privacy of personal and other information regarding participants, educational partners, and joint sponsors. NACCME and our joint sponsors will not release personally identifiable information to a third party without the individual's consent, except such information as is required for reporting purposes to the appropriate accrediting agency.

NACCME maintains physical, electronic, and procedural safeguards that comply with federal regulations to guard your nonpublic personal information.

Copyright © 2011 by North American Center for Continuing Medical Education, LLC. All rights reserved. No part of this accredited continuing education activity may be reproduced or transmitted in any form or by any means, electronic or mechanical, without first obtaining permission from North American Center for Continuing Medical Education.

Grant Support

Supported by an educational grant from Bristol-Myers Squibb Company and Lilly USA, LLC